DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20183476

Cost variation analysis of oral anti-diabetic drugs

Rekha Mehani, Parag Sharma

Abstract


Background: Diabetes Mellitus is a chronic metabolic disorder, one of the major causes of morbidity, mortality and needs lifelong treatment. There are large numbers of oral anti-diabetic drugs available for the treatment of type 2 diabetes mellitus. There are numerous brands available for each of the individual oral anti-diabetic drug. Thus, a study was planned to find out cost variation among different brands of same active oral anti-diabetic drug.

Methods: Cost of a particular drug being manufactured by different companies, in the same strength and dosage forms was obtained from the price list provided by the pharmaceutical companies in Current Index of Medical Specialities (CIMS) (October 2017- January 2018). The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in price was analyzed.

Results: Percentage cost variation of the commonly used drugs found was seen highest with Sulfonylureas (Glimepiride - 562%) followed by Metformin (492%) which was followed by Pioglitazone (488%), DPP-4 inhibitor Teneligliptin (231%), α- glucosidase inhibitors (Voglibose 284%), Meglitinides (Repaglinide 0.5mg 154%) and lowest was seen with Repaglinide 2mg (15%).

Conclusions: There is very wide cost variation among different brands of the same oral anti-diabetic drugs manufactured in India. The average percentage cost variation of different brands of the same oral anti diabetic drugs manufactured in India is very wide. The appraisal and management of marketing drugs should be directed toward maximizing the benefits of therapy and minimizing negative personal and economic consequences.


Keywords


Brands, Cost variation, Cost ratio, Oral anti-diabetic drugs, Pharmacoeconomics

Full Text:

PDF

References


Shrivastava SR, Shrivastava PS, Ramasamy J. Role of self-care in management of diabetes mellitus. J of Diab Metabol Disorde. 2013 Dec;12(1):14.

Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. The Australasian Med J. 2014;7(1):45.

International Diabetes federation. Diabetes atlas. 6th Edition. Available at: www.idf.org/diabetesatlas

Misra A, Khurana L. Obesity-related non-communicable diseases: South Asians vs White Caucasians. Int J Obes (Lond). 2011;35(2):167-87.

Mohan V, Shah S, Saboo B. Current glycemic status and diabetes related complications among type 2 diabetes patients in India: data from the A1chieve study. JAPI (Suppl). 2013;61:12-5.

Mohan V, Seshiah V, Sahay BK, Shah SN, Rao PV Banerjee S. Current status of management of diabetes and glycaemic control in India: Preliminary results from the DiabCare India 2011 Study. Diabetes. 2012;61:a645-a677.

Anjana RM, Ali MK, Pradeepa R, Deepa M, Datta M, Unnikrishnan R, Rema M, Mohan V. The need for obtaining accurate nationwide estimates of diabetes prevalence in India - rationale for a national study on diabetes. Indian J Med Res. 2011;133:369-80.

Sakthivel S. Access to essential drugs and medicines. In: Commission on Macroeconomics and Health. Financing and delivery of health care services in India. New Delhi: Ministry of Health & Family Welfare, Government of India; 2005:185-210.

Shukla AK, Mehani R. Cost analysis of antiepileptic drugs available in India. Int J Basic Clin Pharmacol. 2016;5:1636-40.

Shukla AK, Sharma P. Cost variation study of antidepressant drugs. Int J Basic Clin Pharmacol. 2016;5:1816-21.

Singh A, Kumar H. Cost analysis study of second generation antihistamines used in the treatment of allergic rhinitis in India. Int J Basic Clin Pharmacol. 2016;5(4):1228-33.

Jadhav NB, Bhosale MS, Adhav CV. Cost analysis of study of oral antidiabetic drugs available in Indian market. Int J Med Res Health Sci. 2013;2(!):63-9.

Standards of Medical Care in Diabetes. American Diabetes Association Diabetes Care. 2014 Jan;37(1):S14-S80.

Lalan HN, Borde MK, Ray IM, Deshmukh YA. Cost Variation Study of Antidiabetics: Indian Scenario. Indian J Appl Res. 2014;4(5):420-1.

Rao KS, Nundy M, Dua AS. National commission on macroeconomics and health. financing and delivery of health care services in India. New Delhi: Ministry of Health and Family Welfare, Government of India, Delivery of Health Services in the Private Sector. 2005;89-104.

Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries BMJ Open. 2017;7:e014287.

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160:3.